Clinical Trial Update: Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating toripalimab plus bevacizumab versus sorafenib for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sorafenib (Sorafenib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | Status: UNKNOWN